1. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
by Claudio G. Brunstein, Ephraim J. Fuchs, Shelly L. Carter, Chatchada Karanes, Luciano J. Costa, Juan Wu, Steven M. Devine, John R. Wingard, Omar S. Aljitawi, Corey S. Cutler, Madan H. Jagasia, Karen K. Ballen, Mary Eapen, Paul V. O'Donnell, and
Blood
Volume 118(2):
July 14, 2011
©2011 by American Society of Hematology

2. Treatment plans.
Treatment plans. Treatment schemas for (A) RIC and dUCB transplantation and (B) haplo-marrow transplantation.
Claudio G. Brunstein et al. Blood 2011;118:
©2011 by American Society of Hematology

3. Hematopoietic recovery.
Hematopoietic recovery. Neutrophil (A,C) and platelet recovery (B,D) after RIC and dUCB (A-B) or Haplo-marrow (C-D) transplantation.
Claudio G. Brunstein et al. Blood 2011;118:
©2011 by American Society of Hematology

4. GVHD.
GVHD. Cumulative incidences of acute (A,C) and chronic (B,D) GVHC after RIC with either dUCB transplantation (A-B) or Haplo-marrow transplantation (C-D).
Claudio G. Brunstein et al. Blood 2011;118:
©2011 by American Society of Hematology

5. Long-term outcomes.
Long-term outcomes. Relapse and NRM (A,C), OS, and event-free survival (B,D) after RIC and either dUCB (A-B) or Haplo-marrow transplantation (C-D).
Claudio G. Brunstein et al. Blood 2011;118:
©2011 by American Society of Hematology